Management of transfusional iron overload – differential properties and efficacy of iron chelating agents

References

• CohenARGlimmEPorterJBEffect of transfusional iron intake on response to chelation therapy in {beta}-thalassemia majorBlood2008111258358717951527
   PubMed Web of Science ®Google Scholar
• PorterJGalanelloRSaglioGRelative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-year prospective studyEur J Haematol200880216817618028431
   PubMed Web of Science ®Google Scholar
• BridleKRFrazerDMWilkinsSJDisrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasisLancet2003361935866967312606179
   PubMed Web of Science ®Google Scholar
• AllenKJGurrinLCConstantineCCIron-overload-related disease in HFE hereditary hemochromatosisN Engl J Med2008358322123018199861
   PubMed Web of Science ®Google Scholar
• PhatakPBrissotPWursterMA phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosisHepatology20105251671177920814896
   PubMed Web of Science ®Google Scholar
• FinkenstedtABianchiPTheurlIRegulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiencyBr J Haematol2009144578979319120353
   PubMed Web of Science ®Google Scholar
• TannoTBhanuNVOnealPAHigh levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidinNat Med20071391096110117721544
   PubMed Web of Science ®Google Scholar
• AkrawinthawongKChaowalitNChatuparisuthTSiritanaratkulNEffectiveness of deferiprone in transfusion-independent beta-thalassemia/ HbE patientsHematology201116211312221418744
   PubMed Web of Science ®Google Scholar
• DeerenDDeferasirox in pyruvate kinase deficiencyAnn Hematol200988439718810437
   PubMed Web of Science ®Google Scholar
• LadisVBerdousiHGotsisEKattamisADeferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermediaBr J Haematol2010151550450820950401
   PubMed Web of Science ®Google Scholar
• VoskaridouEPlataEDouskouMTreatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot studyBr J Haematol2009148233233419863539
   PubMed Web of Science ®Google Scholar
• BreuerWHershkoCCabantchikZIThe importance of non-transferrin bound iron in disorders of iron metabolismTransfus Sci200023318519211099894
   PubMedGoogle Scholar
• ZurloMGDe StefanoPBorgna-PignattiCSurvival and causes of death in thalassaemia majorLancet1989227302567801
   PubMed Web of Science ®Google Scholar
• JeanGTerzoliSMauriRCirrhosis associated with multiple transfusions in thalassaemiaArch Dis Child198459167706696498
   PubMed Web of Science ®Google Scholar
• Borgna-PignattiCDe StefanoPZontaLGrowth and sexual maturation in thalassemia majorJ Pediatr198510611501553965675
   PubMed Web of Science ®Google Scholar
• CunninghamMJMacklinEANeufeldEJCohenARComplications of beta-thalassemia major in North AmericaBlood20041041343914988152
   PubMed Web of Science ®Google Scholar
• ThuretIPondarreCLoundouAComplications and treatment of patients with beta-thalassemia in France: results of the National RegistryHaematologica201095572472920007138
   PubMed Web of Science ®Google Scholar
• BrittenhamGMCohenARMcLarenCEHepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia majorAm J Hematol199342181858416302
   PubMed Web of Science ®Google Scholar
• CappelliniMDCohenAPigaAA phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemiaBlood200610793455346216352812
   PubMed Web of Science ®Google Scholar
• VichinskyEOnyekwereOPorterJA randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell diseaseBr J Haematol2007136350150817233848
   PubMed Web of Science ®Google Scholar
• OlivieriNFNathanDGMacMillanJHSurvival in medically treated patients with homozygous beta-thalassemiaN Engl J Med199433195745788047081
   PubMed Web of Science ®Google Scholar
• TelferPTPrestcottEHoldenSWalkerMHoffbrandAVWonkeBHepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia majorBr J Haematol200011097197711054091
   PubMed Web of Science ®Google Scholar
• FilesBBrambillaDKutlarALongitudinal changes in ferritin during chronic transfusion: a report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP)J Pediatr Hematol Oncol200224428429011972097
   PubMed Web of Science ®Google Scholar
• AdamkiewiczTVAbboudMRPaleyCSerum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injuryBlood2009114214632463819721013
   PubMed Web of Science ®Google Scholar
• PakbazZFischerRFungENielsenPHarmatzPVichinskyESerum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patientsPediatr Blood Cancer200749332933217554789
   PubMed Web of Science ®Google Scholar
• AngelucciEBrittenhamGMMcLarenCEHepatic iron concentration and total body iron stores in thalassemia majorN Engl J Med2000343532733110922422
   PubMed Web of Science ®Google Scholar
• CartwrightGEEdwardsCQKravitzKHereditary hemochromatosis. Phenotypic expression of the diseaseN Engl J Med19793014175179449974
   PubMed Web of Science ®Google Scholar
• FarmakiKTzoumariIPappaCChouliarasGBerdoukasVNormalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia majorBr J Haematol2009148346647519912219
   PubMed Web of Science ®Google Scholar
• AndersonLJHoldenSDavisBCardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overloadEur Heart J200122232171217911913479
   PubMed Web of Science ®Google Scholar
• ChirnomasDSGeukes-FoppenMBarryKPractical implications of liver and heart iron load assessment by T2*-MRI in children and adults with transfusion-dependent anemiasAm J Hematol2008831078178318661491
   PubMed Web of Science ®Google Scholar
• VilleneuveJPBilodeauMLepageRCoteJLefebvreMVariability in hepatic iron concentration measurement from needle-biopsy specimensJ Hepatol19962521721778878778
   PubMed Web of Science ®Google Scholar
• BrittenhamGMFarrellDEHarrisJWMagnetic-susceptibility measurement of human iron storesN Engl J Med1982307167116757144866
   PubMed Web of Science ®Google Scholar
• GalanelloRPigaAForniGLPhase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia majorHaematologica200691101343135117018383
   PubMed Web of Science ®Google Scholar
• PigaAGalanelloRForniGLRandomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overloadHaematologica200691787388016818273
   PubMed Web of Science ®Google Scholar
• OlivieriNFBrittenhamGMMatsuiDIron-chelation therapy with oral deferiprone in patients with thalassemia majorN Engl J Med19953329189227877649
   PubMed Web of Science ®Google Scholar
• NielsenPEngelhardtRGrosseRJankaGHarmatzPFischerRItalian Society of Hematology guidelines for thalassemia and non-invasive iron measurementsHaematologica2009942294295 author reply29529619109216
   PubMed Web of Science ®Google Scholar
• BrittenhamGMBadmanDGNoninvasive measurement of iron: report of an NIDDK workshopBlood20031011151912393526
   PubMed Web of Science ®Google Scholar
• WoodJCMagnetic resonance imaging measurement of iron overloadCurr Opin Hematol200714318319017414205
   PubMed Web of Science ®Google Scholar
• St PierreTGClarkPRChua-anusornWNoninvasive measurement and imaging of liver iron concentrations using proton magnetic resonanceBlood2005105285586115256427
   PubMed Web of Science ®Google Scholar
• WestwoodMAWonkeBMaceiraAMLeft ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia majorJ Magn Reson Imaging200522222923316028255
   PubMed Web of Science ®Google Scholar
• WoodJCEnriquezCGhugreNMRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patientsBlood200510641460146515860670
   PubMed Web of Science ®Google Scholar
• KirkPRoughtonMPorterJBCardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia majorCirculation2009120201961196819801505
   PubMed Web of Science ®Google Scholar
• FungEBHarmatzPRLeePDIncreased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell diseaseBr J Haematol2006135457458217054676
   PubMed Web of Science ®Google Scholar
• WoodJCTyszkaMCarsonSNelsonMDCoatesTDMyocardial iron loading in transfusion-dependent thalassemia and sickle cell diseaseBlood20041031934193614630822
   PubMed Web of Science ®Google Scholar
• RoggeroSQuarelloPVinciguerraTLongoFPigaARamenghiUSevere iron overload in Blackfan-Diamond anemia: a case-control studyAm J Hematol2009841172973219810012
   PubMed Web of Science ®Google Scholar
• FungEBHarmatzPMiletMMorbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overloadAm J Hematol200782425526517094096
   PubMed Web of Science ®Google Scholar
• NoetzliLJCoatesTDWoodJCPancreatic iron loading in chronically transfused sickle cell disease is lower than in thalassaemia majorBr J Haematol2011152222923321118197
   PubMed Web of Science ®Google Scholar
• AndersonLJWestwoodMAHoldenSMyocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonanceBr J Haematol2004127334835515491298
   PubMed Web of Science ®Google Scholar
• BrittenhamGMGriffithPMNienhuisAWEfficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia majorN Engl J Med199433195675738047080
   PubMed Web of Science ®Google Scholar
• LeePMohammedNMarshallLIntravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patientsDrug Metab Dispos19932146406448104123
   PubMed Web of Science ®Google Scholar
• CohenARMizaninJSchwartzERapid removal of excessive iron with daily, high-dose intravenous chelation therapyJournal of Pediatrics198911511511552738783
   PubMed Web of Science ®Google Scholar
• FreedmanMHGrisaruDOliveriNMacLuskyIThornerPSPulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusionsAm J Dis Child199014455655692330923
   PubMedGoogle Scholar
• LevineJECohenAMacQueenMMartinMGiardinaPJSensorimotor neurotoxicity associated with high-dose deferoxamine treatmentJ Pediatr Hematol Oncol19971921391419149744
   PubMed Web of Science ®Google Scholar
• FranchiniMGandiniGde GironcoliMVassanelliABorgna–PignattiCApriliGSafety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overloadBlood20009592776277910779420
   PubMed Web of Science ®Google Scholar
• FranchiniMGandiniGVeneriDApriliGSafety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload: an updateBlood2004103274774814702291
   PubMed Web of Science ®Google Scholar
• PippardMJLetskyEACallenderSTWeatherallDJPrevention of iron loading in transfusion-dependent thalassaemiaLancet1978180751178118177945
   PubMed Web of Science ®Google Scholar
• NienhuisAVitamin C and IronN Engl J Med198130431701717442737
   PubMed Web of Science ®Google Scholar
• TaherASheikh-TahaMKoussaSInatiANeemanRMouradFComparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patientsEur J Haematol2001671303411553264
   PubMed Web of Science ®Google Scholar
• WolfeLOliveriNSallanDPrevention of cardiac disease by sucutaneous deferoxamine in patients with thalassemia majorN Engl J Med198531225160016034000198
   PubMed Web of Science ®Google Scholar
• De SanctisVEleftheriouAMalaventuraCPrevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF)Pediatr Endocrinol Rev20042Suppl 224925516462705
   PubMedGoogle Scholar
• BarryMFlynnDMLetskyEARisdonRALong-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progressBr Med J19742590916204821036
   PubMed Web of Science ®Google Scholar
• CohenAMartinMSchwartzEDepletion of excessive liver iron stores with desferrioxamineBr J Haematol1984583693736477838
   PubMed Web of Science ®Google Scholar
• DavisBAPorterJBLong-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemiaBlood20009541229123610666195
   PubMed Web of Science ®Google Scholar
• OlivieriNFBuncicJRChewEVisual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusionsN Engl J Med1986314148698733485251
   PubMed Web of Science ®Google Scholar
• De SanctisVPinamontiADiPalmaAGrowth and development in thalassemia major patients with severe bone lesions due to desferrioxamineEur J Pediatr199615553683728741032
   PubMed Web of Science ®Google Scholar
• PorterJBJaswonMSHuehnsEREastCAHazellJWDesferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosageBr J Haematol19897334034092605127
   PubMed Web of Science ®Google Scholar
• AdamkiewiczTVBerkovitchMKrishnanCPolsinelliCKermackDOlivieriNFInfection due to Yersinia enterocolitica in a series of patients with beta-thalassemia: incidence and predisposing factorsClin Infect Dis1998276136213669868642
   PubMed Web of Science ®Google Scholar
• ChanGCChanSHoPLHaSYEffects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patientsHemoglobin200933535236019814682
   PubMed Web of Science ®Google Scholar
• DeleaTEEdelsbergJSofryginOConsequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature reviewTransfusion200747101919192917880620
   PubMed Web of Science ®Google Scholar
• WardACaroJJGreenTCAn international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine useBMC Clin Pharmacol20022312015817
   PubMedGoogle Scholar
• BeratisSNoncompliance with iron chelation therapy in patients with beta thalassaemiaJ Psychosom Res19893367397452695624
   PubMed Web of Science ®Google Scholar
• Borgna-PignattiCRugolottoSDeStefanoPSurvival and disease complications in thalassemia majorAnn N Y Acad Sci19988502272319668544
   PubMed Web of Science ®Google Scholar
• CeciABaiardiPCatapanoMRisk factors for death in patients with beta-thalassemia major: results of a case-control studyHaematologica200691101420142116963395
   PubMed Web of Science ®Google Scholar
• KontoghiorghesGJPattichisKNeocleousKKolnagouAThe design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospectsCurr Med Chem200411162161218315279556
   PubMed Web of Science ®Google Scholar
• Al-RefaieFNSheppardLNNorteyPWonkeBHoffbrandAVPharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overloadBr J Haematol1995894034087873392
   PubMed Web of Science ®Google Scholar
• MatsuiDKleinJHermannCRelationship between the pharmacokinetics and iron excretion of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-1 in patients with thalassemiaClin Pharmacol Ther19915032942981914364
   PubMed Web of Science ®Google Scholar
• El AlfyMSariTTLeeCLTrictaFEl-BeshlawyAThe safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overloadJ Pediatr Hematol Oncol201032860160520921906
   PubMed Web of Science ®Google Scholar
• CollinsAFFassosFFStobieSIron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell diseaseBlood1994838232923338161801
   PubMed Web of Science ®Google Scholar
• OlivieriNFKorenGHermannCComparison of oral iron chelator L1 and desferrioxamine in iron-loaded patientsLancet19903368726127512791978115
   PubMed Web of Science ®Google Scholar
• AgarwalMBGupteSSViswanathanCLong-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trialBr J Haematol19928224604661419829
   PubMed Web of Science ®Google Scholar
• Al-RefaieFNWonkeBHoffbrandAVWickensDGNorteyPKontoghiorgesGJEfficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia majorBlood19928035935991638018
   PubMed Web of Science ®Google Scholar
• WonkeBWrightCHoffbrandAVCombined therapy with deferiprone and desferrioxamineBr J Haematol19981033613649827905
   PubMed Web of Science ®Google Scholar
• KerstenMJLangeRSmeetsMELong-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trialAnn Hematol19967352472528959943
   PubMed Web of Science ®Google Scholar
• MaggioAD’AmicoGMorabitoADeferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trialBlood Cells Mol Dis200228219620812064916
   PubMed Web of Science ®Google Scholar
• Al-RefaieFNHershkoCHoffbrandAVResults of long-term deferiprone (L1) therapy: a report by the International Study Group on oral iron chelatorsBr J Haematol19959112242297577638
   PubMed Web of Science ®Google Scholar
• CeciABaiardiPFelisiMThe safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patientsBr J Haematol2002118133033612100170
   PubMed Web of Science ®Google Scholar
• CohenARGalanelloRPigaADiPalmaAVulloCTrictaFSafety profile of the oral iron chelator deferiprone: a multicentre studyBr J Haematol2000108230531210691860
   PubMed Web of Science ®Google Scholar
• HoffbrandAVAl-RefaieFDavisBLong-term trial of deferiprone in 51 transfusion-dependent iron overloaded patientsBlood19989112953009414297
   PubMed Web of Science ®Google Scholar
• CohenARGalanelloRPigaADeSanctisVTrictaFSafety and effectiveness of long-term therapy with the oral iron chelator deferiproneBlood200310251583158712763939
   PubMed Web of Science ®Google Scholar
• MazzaPAmurriBLazzariGOral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemiaHaematologica19988364965019676021
   PubMed Web of Science ®Google Scholar
• OlivieriNFBrittenhamGMMcLarenCELong-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia majorN Engl J Med199833974174239700174
   PubMed Web of Science ®Google Scholar
• PennellDJBerdoukasVKaragiorgaMRandomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosisBlood200610793738374416352815
   PubMed Web of Science ®Google Scholar
• TaherASheikh-TahaMShararaASafety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year studyActa Haematol2005114314614916227677
   PubMed Web of Science ®Google Scholar
• Borgna-PignattiCCappelliniMDDe StefanoPCardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia majorBlood200610793733373716373663
   PubMed Web of Science ®Google Scholar
• PigaAGagliotiCFogliaccoETrictaFComparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysisHaematologica200388548949612745268
   PubMed Web of Science ®Google Scholar
• AndersonLJWonkeBPrescottEHoldenSWalkerJMPennellDJComparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemiaLancet2002360933251652012241655
   PubMed Web of Science ®Google Scholar
• BerdoukasVChouliarasGMoraitisPZannikosKBerdoussiELadisVThe efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational studyJ Cardiovasc Magn Reson2009112019558722
   PubMed Web of Science ®Google Scholar
• Al-RefaieFNWonkeBHoffbrandAVDeferiprone-associated myelotoxicityEur J Haematol19945352983017813710
   PubMed Web of Science ®Google Scholar
• HenterJIKarlenJFatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemiaBlood2007109125157515917344464
   PubMed Web of Science ®Google Scholar
• HoffbrandAVBartlettANVeysPAO’ConnorNTKontoghiorghesGJAgranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trialLancet1989286604572569644
   PubMed Web of Science ®Google Scholar
• TonduryPZimmermanANielsenPHirtALiver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patientsBr J Haematol199810134134159633879
   PubMed Web of Science ®Google Scholar
• WanlessIRSweeneyGDhillonAPLack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemiaBlood200210051566156912176871
   PubMed Web of Science ®Google Scholar
• GalanelloRPigaAAlbertiDRouanMCBiglerHSechaudRSafety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemiaJ Clin Pharmacol200343656557212817519
   PubMed Web of Science ®Google Scholar
• GalanelloRPigaACappelliniMDEffect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimenJ Clin Pharmacol200848442843518281442
   PubMed Web of Science ®Google Scholar
• Nisbet-BrownEOlivieriNFGiardinaPJEffectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trialLancet200336193691597160212747879
   PubMed Web of Science ®Google Scholar
• ChirnomasDSmithALBraunsteinJDeferasirox pharmacokinetics in patients with adequate versus inadequate responseBlood2009114194009401319724055
   PubMed Web of Science ®Google Scholar
• TaherACappelliniMDVichinskyEEfficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overloadBr J Haematol2009147575275919764988
   PubMed Web of Science ®Google Scholar
• PennellDJPorterJBCappelliniMDEfficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemiaBlood2010115122364237119996412
   PubMed Web of Science ®Google Scholar
• PennellDJPorterJBCappelliniMDContinued improvement in myocardial T2* over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overloadHaematologica2011961485421071497
   PubMed Web of Science ®Google Scholar
• WoodJCKangBPThompsonAThe effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron storesBlood2010116453754320421452
   PubMed Web of Science ®Google Scholar
• PathareATaherADaarSDeferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia majorAnn Hematol201089440540919798501
   PubMed Web of Science ®Google Scholar
• TradOHamdanMAJamilAReversal of iron-induced dilated cardiomyopathy during therapy with deferasirox in beta-thalassemiaPediatr Blood Cancer200952342642818985743
   PubMed Web of Science ®Google Scholar
• KiguchiTItoYKimuraYOhyashikiKRestoration of cardiac function by an iron chelator, deferasirox, in a patient with aplastic anemia and cardiac iron overloadInt J Hematol200989454654819363706
   PubMed Web of Science ®Google Scholar
• RheaultMNBechtelHNegliaJPKashtanCEReversible Fanconi syndrome in a pediatric patient on deferasiroxPediatr Blood Cancer201156467467621298760
   PubMed Web of Science ®Google Scholar
• WeiHYYangCPChengCHLoFSFanconi syndrome in a patient with beta-thalassemia major after using deferasirox for 27 monthsTransfusion201151594995421077910
   PubMed Web of Science ®Google Scholar
• YacobovichJStarkPBarzilai-BirenbaumSAcquired proximal renal tubular dysfunction in beta-thalassemia patients treated with deferasiroxJ Pediatr Hematol Oncol201032756456720733517
   PubMed Web of Science ®Google Scholar
• BautersTMondelaersVRobaysHHunninckKde MoerlooseBGastric ulcer in a child treated with deferasiroxPharm World Sci201032211211320063122
   PubMedGoogle Scholar
• KwiatkowskiJLKimH-YThompsonAAChelation choices and iron burden among patients with thalassemia in the 21st century: a report from the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort [Abstract]Blood2009114224056
   Web of Science ®Google Scholar
• CappelliniMDBejaouiMAgaogluLProspective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemiaClin Ther200729590991717697909
   PubMed Web of Science ®Google Scholar
• OrigaRBinaPAgusACombined therapy with deferiprone and desferrioxamine in thalassemia majorHaematologica200590101309131416219566
   PubMed Web of Science ®Google Scholar
• KattamisALadisVBerdousiHIron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trialBlood Cells Mol Dis2006361212516386928
   PubMed Web of Science ®Google Scholar
• BreuerWErmersMJJPootrakulPAbramovAHershkoCCabantchikZIDesferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapyBlood200197379279811157499
   PubMed Web of Science ®Google Scholar
• LinkGKonijnAMBreuerWCabantchikZIHershkoCExploring the “iron shuttle” hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in cultureJ Lab Clin Med2001138213013811477380
   PubMed Web of Science ®Google Scholar
• TannerMAGalanelloRDessiCA randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonanceCirculation2007115141876188417372174
   PubMed Web of Science ®Google Scholar
• TannerMAGalanelloRDessiCCombined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunctionJ Cardiovasc Magn Reson2008101218298856
   PubMed Web of Science ®Google Scholar
• LaiMEGradyRWVacquerSIncreased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine aloneBlood Cells Mol Dis201045213613920678715
   PubMed Web of Science ®Google Scholar
• ChristoforidisAHaritandiATsatraITsitouridesIKarydaSAthanassiou-MetaxaMFour-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimensEur J Haematol2007781525717042760
   PubMed Web of Science ®Google Scholar
• Otto-DuesselMBrewerCGonzalezINickHWoodJCSafety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overloadActa Haematol2008120212312819018129
   PubMed Web of Science ®Google Scholar
• JetsrisuparbAKomvilaisakPWiangnonSJetsrisuparbCRetrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 yearsJ Pediatr Hematol Oncol201032540040320505533
   PubMed Web of Science ®Google Scholar
• LalASweetersNHerzMSafety of combined chelation therapy with deferasirox and deferoxamine in transfusion-dependent thalassemia [Abstract]Blood2009114222021
   Web of Science ®Google Scholar
• BaloccoMCarraraPPintoVForniGLDaily alternating deferasirox and deferiprone therapy for “hard-to-chelate” beta-thalassemia major patientsAm J Hematol201085646046120513129
   PubMed Web of Science ®Google Scholar
• BerdoukasVCarsonSNordACombining two orally active iron chelators for thalassemiaAnn Hematol201089111177117820217085
   PubMed Web of Science ®Google Scholar
• RienhoffHYJrViprakasitVTayLA phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overloadHaematologica201196452152521173101
   PubMed Web of Science ®Google Scholar